About Elixirgen Therapeutics
Elixirgen Therapeutics is a private company based in Baltimore, Maryland. It has reported $34,106,860 raised in eight offerings on Form D since June 2018. Its chief executive is Akihiro Ko.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 30, 2025 | Nov 13, 2025 | $4,000,000fully sold | 1 | $4.0M | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Mar 31, 2025 | Apr 9, 2025 | $3,600,000fully sold | 2 | $1.8M | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 30, 2025 | Feb 12, 2025 | $600,000fully sold | 2 | $300K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 9, 2023 | Dec 1, 2023 | $6,999,988fully sold | 1 | $6.9M | EquityRule 506(b) | Form D ↗ |
| Sep 14, 2022 | Sep 29, 2022 | $5,000,000fully sold | 1 | $5.0M | DebtRule 506(b) | Form D ↗ |
| Feb 2, 2021 | Feb 18, 2021 | $4,199,985of $5.4M target | 2 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Nov 19, 2019 | Dec 2, 2019amended Aug 17, 2020 | $5,706,889fully sold | 3 | $1.9M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 13, 2018 | Jun 25, 2018 | $3,999,998fully sold | 1 | $3.9M | EquityRule 506(b) | Form D ↗ |
| Total, eight offerings | $34,106,860 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Elixirgen Therapeutics's Form D filed Nov 13, 2025.
HK
Hiroaki Kobayashi
Director
TW
Thomas White
Director
Jeffrey Cleland
Director
Also an executive officer, director and promoter at Ironfist Therapeutics and Nanopower Medicine and a director at Syncromune.
MK
Minoru Ko
Director
SC
Shauna Callahan
Director
AK
Akihiro Ko
CEO and director
Earlier filings also listed Maiko Katadae (director, last listed Sep 2022) and Naonori Kurokawa (director, last listed Feb 2021).